Cargando…
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
Autores principales: | Lumry, William R., Zuraw, Bruce, Cicardi, Marco, Craig, Timothy, Anderson, John, Banerji, Aleena, Bernstein, Jonathan A., Caballero, Teresa, Farkas, Henriette, Gower, Richard G., Keith, Paul K., Levy, Donald S., Li, H. Henry, Magerl, Markus, Manning, Michael, Riedl, Marc A., Lawo, John-Philip, Prusty, Subhransu, Machnig, Thomas, Longhurst, Hilary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317315/ https://www.ncbi.nlm.nih.gov/pubmed/34321052 http://dx.doi.org/10.1186/s13023-021-01975-2 |
Ejemplares similares
-
Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study
por: Lumry, William R., et al.
Publicado: (2021) -
Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study
por: Li, H. Henry, et al.
Publicado: (2019) -
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks
por: Riedl, Marc A., et al.
Publicado: (2020) -
Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies
por: Busse, Paula J., et al.
Publicado: (2018) -
Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema
por: Zhang, Ying, et al.
Publicado: (2018)